Immunotherapies have been hailed as a game changer in the treatment of head and neck cancers. However there are currently no means by which to identify whether a patient will respond to therapy. In this project, we aim to assess the tumour spatially and genetically to develop a means by which to predict response to immunotherapy. In so doing, targeting therapies to those head and neck cancer patients that are likely to achieve the greatest benefit.